title: Continuous infusion of FVIII and FIX concentrates: in vitro analysis of clinically relevant parameters.
abstract: A high purity factor VIII/von Willebrand Factor (FVIII/vWF) concentrate (IMMUNATE [STIM plus]) (n = 6 batches), and a high purity factor IX (FIX) concentrate (IMMUNINE [STIM plus]) (n = 7 batches), were assessed in vitro for their applicability to continuous infusion. Parameters pertinent to continuous infusion were investigated and included stability, sterility and, in the case of FIX, the generation of potentially thrombogenic components. Four stationary or transportable mini infusion pumps, equipped with polyethylene, polypropylene or polyvinylchloride plastic components were used. The concentrates were reconstituted without extra filling volume and perfused at 12.5 mL h-1 and 1 mL h-1; sampling was carried out at the start of the experiment and for up to 48 h. The FVIII procoagulant activity (FVIII:C) was assayed by amidolytic, 1-stage and 2-stage assays; vWF was examined for ristocetin cofactor activity, antigen and multimers. The FIX coagulation activity (FIX:C) was determined by a 1-stage coagulation assay; thrombogenicity potential was assessed in vivo (Wessler stasis model in rabbits) and in vitro (FIXa and nonactivated thromboplastin time). Reconstituted concentrate incubated under the same conditions served as a control. Both concentrates remained sterile throughout the testing period. The perfused and control samples remained stable, retaining over 95% of activity for FVIII:C and over 90% for FIX:C for up to 48 h. Intermittent decrease of FVIII:C or FIX:C was not observed, suggesting no adsorption of FVIII or FIX onto plastic surfaces during either short or long-term exposure. No thrombogenic components were detected in the high purity FIX concentrate. Thus, under the in vitro conditions used, FVIII/vWF and FIX were found to be suitable for administration by continuous infusion.
authors.affiliation: Hyland Immuno Division, Baxter Healthcare, Vienna, Austria.
authors.forename: K B
authors.initials: KB
authors.lastname: Thomas
authors.forename: W
authors.initials: W
authors.lastname: Urbancik
authors.forename: P L
authors.initials: PL
authors.lastname: Turecek
authors.forename: H
authors.initials: H
authors.lastname: Gritsch
authors.forename: J
authors.initials: J
authors.lastname: Schreiber
authors.forename: A
authors.initials: A
authors.lastname: Weber
authors.forename: W
authors.initials: W
authors.lastname: Schönhofer
authors.forename: M
authors.initials: M
authors.lastname: Strauss
authors.forename: Y
authors.initials: Y
authors.lastname: Linnau
authors.forename: A
authors.initials: A
authors.lastname: Schoppmann
mesh_terms: D001780:Blood Coagulation Tests; D005164:Factor IX / Q000008:administration & dosage* / Q000009:adverse effects; D005169:Factor VIII / Q000008:administration & dosage* / Q000009:adverse effects; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007260:Infusion Pumps; D007262:Infusions, Intravenous; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D013242:Sterilization; D019851:Thrombophilia / Q000139:chemically induced
chemical_list: D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX